May 29, 2025 07:30 PM EDT

Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences

Lei Lei Wu

News Reporter

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a Claudin18.2-targeted antibody-drug conjugate from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences

Lei Lei Wu

News Reporter

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit’s disappointing survival readout raises stakes for full data

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Summit says bispecific misses overall survival in closely-watched lung cancer study

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Astel­las li­cens­es Claudin18.2 ADC from Chi­na’s Evo­point Bio­sciences

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences